Marc Humbert, M.D., Ph.D.
Marc Humbert, M.D., Ph.D., is Professor of Respiratory Medicine at the South Paris University (Université Paris-Saclay) in Le Kremlin-Bicêtre, France since 1999. In addition to his academic responsibilities, he is the Director of the National Reference Centre for Pulmonary Hypertension, Department of Respiratory and Intensive Care Medicine, Hospital Bicêtre, Assistance Publique Hôpitaux de Paris, France. Along with membership to several scientific councils and institutes, Marc Humbert is the current Director of the INSERM Unit “Pulmonary Hypertension: Pathophysiology and Innovative Therapies” and of the “Thorax Innovation” University Hospital Department. He has been the Chief Editor of the European Respiratory Journal from 2013 to 2017. He has published more than 700 peer-reviewed articles, mostly in the field of pulmonary hypertension. He is a Fellow of the European Respiratory Society (FERS Foundation Fellow) and has received several distinctions including the 1997 François Brenot Award and the 2006 Cournand Lecture Award from the ERS, the 2009 Descartes-Huygens Award from the Royal Netherlands Academy of Arts and Sciences, the 2016 Rare Disease Award of the Fondation de France and the 2018 ERS Award for Lifetime Achievement in Pulmonary Arterial Hypertension. Since 2017, Marc Humbert is the vice-coordinator of the European Reference Network for rare and low prevalence respiratory diseases (ERN-LUNG). Clarivate Analytics listed Marc Humbert as one of the world’s highly cited researchers in the field of Clinical Medicine (2018).
R. James White III, M.D., Ph.D.
Dr. Jim White has spent twenty years at the University of Rochester Medical Center (URMC) and is the founding director of the University’s pulmonary arterial hypertension (PAH) program. He has been the principal investigator for Phase 2 and 3 programs conducted there and is now sharing that responsibility with his partner, Dan Lachant. URMC is the region’s leading referral center for patients with pulmonary vascular diseases and has received accreditation as a Comprehensive Care Center from the Pulmonary Hypertension Association in recognition of excellence in diagnosis, research and clinical care.
In his bench laboratory, Dr. White’s research focuses on understanding the vascular biology of PAH and serving as a test ground to compare late stage preclinical compounds to currently available treatments. He has participated in clinical trials for numerous experimental PAH medications, including tadalafil, ambrisentan, riociguat, bardoxolone, and rituxan (in scleroderma-associated PAH.) He is the academic leader for the development of oral treprostinil.
In addition to his clinical and academic responsibilities, Dr. White provides scientific and development advice to biopharmaceutical companies including PhaseBio, United Therapeutics, Reata Pharmaceuticals, Gilead, Bayer and Celtaxsys. He has published over 30 clinical articles and was awarded a patent in 2005 for the use of tissue factor pathway inhibitors and protease activated receptor 1 antagonists for the treatment of PAH.
Dr. White earned his M.D. and Ph.D. degrees while in an NIH-funded Medical Scientist Training Program at the University of Pittsburgh under the mentorship of Dr. Ian Reynolds. Thereafter, he completed residency training in internal medicine and a fellowship in pulmonary and critical care at the University of Rochester.
Mandy MacLean, Ph.D.
Professor MacLean obtained her Ph.D. in Pharmacology from the University of Edinburgh in 1985 and then spent a year in the USA and three years in Cambridge before moving to The University of Glasgow in 1989. She currently is Professor of Pulmonary Pharmacology at the University of Strathclyde. Her research over the last 25 years has focused on the role of serotonin in the development of pulmonary arterial hypertension (PAH). As more women get PAH than men, more recently her work has focused on sex effects and oestrogen metabolism in PAH. She recently won the 2017 Reynold Spector Award for Clinical Pharmacology from the American Society for Pharmacology and Experimental Therapeutics (ASPET). Other research awards include a Royal Society Wolfson Research Merit Award in 2010 and a Royal Society Leverhulme Trust Senior Research Fellowship in 2013. In 2013 she was elected as a Fellow of The Royal Society of Edinburgh (FRSE) and awarded the British Pharmacological Society AstraZeneca Prize for Women in Pharmacology. She was elected as an Ordinary Member and Trustee of Council for the Royal Society of Edinburgh and is now Vice-President (Life Sciences) of the Royal Society of Edinburgh. Mandy received an MBE in the 2010 Queen’s New Years Honours list for her career and public engagement activities. In 2018 she was made a Fellow of the Academy of Medical Sciences and has just been appointed the Scottish Champion for the Academy of Medical Sciences.